Novel Perspectives in Pseudomyxoma Peritonei Treatment

Area of Science:

• Oncology
• Surgical Oncology
• Gastroenterology

Background:

• Pseudomyxoma Peritonei (PMP) is a rare condition characterized by neoplastic cell implantation and mucin production within the peritoneum.
• The rarity of PMP limits the ability to conduct randomized controlled trials for treatment evaluation.

Purpose of the Study:

• To review the epidemiology, pathogenesis, clinical presentation, and treatment of PMP.
• To explore molecular factors in PMP progression and mucin production for improved patient selection and therapeutic strategies.

Main Methods:

• Literature review of Pseudomyxoma Peritonei.
• Analysis of current treatment modalities, including Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
• Discussion of molecular targets for future therapies.

Main Results:

• Cytoreductive Surgery (CRS) combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is the primary curative treatment for PMP.
• Molecular factors influencing tumor progression and mucin production are key areas for future research.

Conclusions:

• CRS and HIPEC represent the most effective treatment for Pseudomyxoma Peritonei, offering potential for cure.
• Understanding molecular mechanisms is crucial for advancing PMP patient selection and treatment options.